AKT1 and prostate carcinoma: We demonstrated that treatment with a PI3K inhibitor and Akt inhibitor inhibited BK-induced cell motility and ICAM-1 expression, suggesting that PI3K/Akt activation is a requisite event in BK-increased cell migration in prostate cancer cells.